Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(6)
•••
Comment by BearDownAZon Feb 26, 2016 7:53am
187 Views
Post# 24597672

RE:RE:RE:RE:RE:Nice buying by ITG Canada today.

RE:RE:RE:RE:RE:Nice buying by ITG Canada today.The panel discussion and company presentation may or may not have went well earlier this week. Unless one attended the conference or directly reaches out to the company in hopes of getting some info, how are we to know?

BiOasis has pretty much gone silent on the public relations front. If one goes to the Bioasis website, one can't even find the latest news release about the Neuroscience Partnering and BioInvestment forum (it's on SEDAR though). The latest presentation available on the website in the Q1 2015 presentation. In the past 6 1/2 months, the only CEO Blog has been the "Why BiOasis Matters" entry from over 2 months ago that ended with "I know what will be a prosperous new year."  After regular updates to the Science Blog from May to September 2015, it has gone silent with no updates in 5 months. The Fall Summary report 10 minute video from October 21, 2015 and the very short Holiday Note video from December 28, 2015 that simply repeated the 2015 highlights is really the only substance currently on the website. There is no schedule of events on their website. The only article listed on their website in almost 3 years is a general review on breaking the blood brain barrier and the only Bioasis authored article listed is from almost 8 years ago!

We need an updated BiOasis website!

BearDownAZ
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities